StockNow
Log in
U.S. Markets

Amgen Inc. (AMGN) Q2 2026 (USD): Adj. EPS 6.29 (exp. 5.62), Revenue 10.1bln (exp. 9.43bln)

StockNow breaking-news AI analysis

Amgen delivered a strong Q2 2026 beat and raised full-year guidance, driven by key product volume growth and biosimilar momentum, despite patent erosion for Prolia and Xgeva.

News detail

Outlook FY adj, EPS 22.30-23.50 (exp. 22.36). FY revenue 38.2-39.4bln (exp. 37.7bln).

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYU.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)

Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement